- Corporate Officers - B
- Boyce Sarah
Insider Trading History of Boyce Sarah
The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Boyce Sarah since 2016.
This trader's CIK number is 1629383.
At the time of last reporting, Boyce Sarah was the President and CEO of Avidity Biosciences, Inc.. (stock ticker symbol RNA).
Also see all insider trading activities at Avidity Biosciences, Inc..
Note that in the past
Boyce Sarah also reported insider trading activities as an insider of the following companies:
Yearly summary of insider trading at Ionis Pharmaceuticals Inc (IONS) by Boyce Sarah
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2018 | IONS | 0 | $0 | 2,196 | $113,664 | 5,367 | $0 |
| 2017 | IONS | 0 | $0 | 1,361 | $63,000 | 3,483 | $0 |
| 2016 | IONS | 0 | $0 | 872 | $36,150 | 2,188 | $0 |
Yearly summary of insider trading at Avidity Biosciences, Inc. (RNA) by Boyce Sarah
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2025 | RNA | 0 | $0 | 66,937 | $2,511,560 | 25,000 | $31,000 |
| 2024 | RNA | 0 | $0 | 737,901 | $24,053,413 | 636,000 | $788,639 |
| 2023 | RNA | 0 | $0 | 50,000 | $1,217,735 | 50,000 | $61,999 |
| 2022 | RNA | 0 | $0 | 50,000 | $1,143,856 | 50,000 | $61,999 |
Yearly summary of insider trading at Bruker Cellular Analysis, Inc. (BLI) by Boyce Sarah
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2021 | BLI | 0 | $0 | 10,000 | $611,930 | 10,000 | $89,000 |
Yearly summary of insider trading at Omniab, Inc. (OABI) by Boyce Sarah
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2024 | OABI | 0 | $0 | 0 | $0 | 20,000 | $0 |
Yearly summary of insider trading at Akcea Therapeutics, Inc. (AKCA) by Boyce Sarah
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2019 | AKCA | 0 | $0 | 1,819 | $42,782 | 0 | $0 |
Insider trading activities at 5 companies by Boyce Sarah:
1. Ionis Pharmaceuticals Inc (IONS)
2. Avidity Biosciences, Inc. (RNA)
3. Bruker Cellular Analysis, Inc. (BLI)
4. Omniab, Inc. (OABI)
5. Akcea Therapeutics, Inc. (AKCA)
Table 1. Insider trading of Ionis Pharmaceuticals Inc (IONS) by Boyce Sarah
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2018-01-16 | IONS | Sale | 2,196 | 51.76 | 113,664 |
| 2018-01-15 | IONS | Option Ex | 5,367 | .00 | 0 |
| 2017-01-15 | IONS | Option Ex | 3,483 | .00 | 0 |
| 2017-01-17 | IONS | Sale | 1,361 | 46.29 | 63,000 |
| 2016-01-15 | IONS | Option Ex | 2,188 | .00 | 0 |
| 2016-01-19 | IONS | Sale | 872 | 41.46 | 36,150 |
Table 2. Insider trading of Avidity Biosciences, Inc. (RNA) by Boyce Sarah
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2025-08-28 | RNA | Option Ex | 25,000 | 1.24 | 31,000 |
| 2025-08-28 | RNA | Sale | 25,000 | 49.39 | 1,234,700 |
| 2025-03-20 | RNA | Sale | 31,540 | 31.06 | 979,569 |
| 2025-01-21 | RNA | Sale | 10,397 | 28.59 | 297,291 |
| 2024-12-18 | RNA | Sale | 31,855 | 32.66 | 1,040,384 |
| 2024-09-23 | RNA | Sale | 32,880 | 44.00 | 1,446,720 |
| 2024-08-06 | RNA | Option Ex | 28,000 | 1.24 | 34,720 |
| 2024-08-06 | RNA | Sale | 28,000 | 43.35 | 1,213,828 |
| 2024-07-09 | RNA | Option Ex | 28,000 | 1.24 | 34,720 |
| 2024-07-09 | RNA | Sale | 28,000 | 39.93 | 1,118,096 |
| 2024-06-18 | RNA | Sale | 32,074 | 39.13 | 1,255,055 |
| 2024-06-12 | RNA | Option Ex | 100,000 | 1.24 | 124,000 |
| 2024-06-13 | RNA | Option Ex | 164,233 | 1.24 | 203,648 |
| 2024-06-14 | RNA | Sale | 35,767 | 40.08 | 1,433,469 |
| 2024-06-13 | RNA | Sale | 164,233 | 40.08 | 6,581,801 |
| 2024-06-14 | RNA | Option Ex | 35,767 | 1.24 | 44,351 |
| 2024-06-12 | RNA | Sale | 100,000 | 35.73 | 3,572,999 |
| 2024-06-04 | RNA | Option Ex | 28,000 | 1.24 | 34,720 |
| 2024-06-04 | RNA | Sale | 28,000 | 27.42 | 767,788 |
| 2024-05-07 | RNA | Sale | 28,000 | 25.54 | 715,064 |
| 2024-05-07 | RNA | Option Ex | 28,000 | 1.24 | 34,720 |
| 2024-04-02 | RNA | Option Ex | 28,000 | 1.24 | 34,720 |
| 2024-04-02 | RNA | Sale | 28,000 | 26.25 | 734,916 |
| 2024-03-08 | RNA | Sale | 84,000 | 21.39 | 1,796,676 |
| 2024-03-12 | RNA | Option Ex | 28,000 | 1.24 | 34,720 |
| 2024-03-12 | RNA | Sale | 28,000 | 22.63 | 633,696 |
| 2024-03-08 | RNA | Option Ex | 84,000 | 1.24 | 104,160 |
| 2024-03-01 | RNA | Option Ex | 84,000 | 1.24 | 104,160 |
| 2024-03-01 | RNA | Sale | 84,000 | 20.14 | 1,691,340 |
| 2024-01-22 | RNA | Sale | 5,092 | 10.13 | 51,581 |
| 2023-02-03 | RNA | Sale | 3,221 | 24.26 | 78,141 |
| 2023-02-02 | RNA | Sale | 45,879 | 24.36 | 1,117,750 |
| 2023-02-03 | RNA | Option Ex | 3,221 | 1.24 | 3,994 |
| 2023-02-01 | RNA | Sale | 900 | 24.27 | 21,844 |
| 2023-02-01 | RNA | Option Ex | 900 | 1.24 | 1,116 |
| 2023-02-02 | RNA | Option Ex | 45,879 | 1.24 | 56,889 |
| 2022-08-25 | RNA | Sale | 14,855 | 23.07 | 342,689 |
| 2022-08-24 | RNA | Sale | 35,045 | 22.80 | 798,920 |
| 2022-08-25 | RNA | Option Ex | 14,855 | 1.24 | 18,420 |
| 2022-08-24 | RNA | Option Ex | 35,045 | 1.24 | 43,455 |
| 2022-08-15 | RNA | Option Ex | 100 | 1.24 | 124 |
| 2022-08-15 | RNA | Sale | 100 | 22.47 | 2,247 |
Table 3. Insider trading of Bruker Cellular Analysis, Inc. (BLI) by Boyce Sarah
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2021-03-01 | BLI | Sale | 10,000 | 61.19 | 611,930 |
| 2021-03-01 | BLI | Option Ex | 10,000 | 8.90 | 89,000 |
Table 4. Insider trading of Omniab, Inc. (OABI) by Boyce Sarah
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2024-06-18 | OABI | Option Ex | 20,000 | .00 | 0 |
Table 5. Insider trading of Akcea Therapeutics, Inc. (AKCA) by Boyce Sarah
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2019-07-15 | AKCA | Sale | 1,819 | 23.52 | 42,782 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Boyce Sarah
(President and CEO of Avidity Biosciences, Inc. at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.